N/A
N=64
Effect of Inflammation on Pharmacokinetics of Posaconazole
Mycoses
Bottom Line
View on ClinicalTrials.gov: NCT02492802 ↗Enrolled (actual)
64
Serious AEs
0.0%
Results posted
Jun 2019
Primary outcome: Primary: C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/L — 1.8; 23.5 mg/L — p=0.77
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- posaconazole (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University Medical Center Groningen
- Primary completion
- Jun 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/L |
1.8; 23.5 | 0.77 |
Summary
Posaconazole plasma concentration and inflammatory markers will be determined in all samples available from routine analysis.
Eligibility Criteria
Inclusion Criteria
- >18 yrs
- receiving posaconazole
- Written informed consent
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT02492802). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.